Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia

Bone Marrow Transplantation

Volumn 23, Issue 11, 1999, Pages 1095-1100

  Jillella, A P ^a,b   Doria, R ^a   Khan, K ^a   Zelterman, D ^a   Ahmad, Y H ^a   Smith, B R ^a   Holmes, W ^a   Becker, P ^a   Roberts, K B ^a   Rappeport, J M ^a  

^a YALE CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

ara C; Bone marrow transplant; Cyclophosphamide; Leukemia; Myeloablation; Preparative regimen; Veno occlusive disease

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ATAXIA; CANCER SURVIVAL; CEREBELLUM DISEASE; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DYSARTHRIA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NYSTAGMUS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; VOMITING; WHOLE BODY RADIATION;

EID: 0032972923     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701786     Document Type: Article

References (30)

1. Thomas ED. Marrow transplantation for malignant disease. J Clin Oncol 1983; 1: 517-531.
2. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia cooperative groups. New Engl J Med 1995; 332: 217-223.
3. Van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
4. Forman SJ. The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults. Leukemia 1997; 11 (Suppl. 4): S18-S19.
5. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
6. Copelan EA, Biggs JC, Szer J et al. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin Oncol 1993; 20: 33-38.
7. Zhang MJ, Hoelzer D, Horowitz MM et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med 1995; 123: 428-431.
8. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan vs cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263-2268.
9. Snyder DS, Negrin RS, O'Donnell MR et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994; 84: 1672-1679.
10. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
11. Brown RA, Wolff SN, Fay JW et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 1995; 85: 1391-1395.
12. McGlave P. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 1990; 27 (Suppl. 4): 23-30.
13. Mortimer M, Bortin A, Barrett J et al. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980s: a report from the IBMTR. Leukemia 1992; 6 (Suppl. 2): 196-197.
14. Weisdorf DJ, Woods WG, Nesbit ME et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia: risk factors and clinical outcome. Br J Haematol 1994; 86: 62-69.
15. Herzig RH, Coccia PF, Lazarus HM et al. Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation. Semin Oncol 1985; 12: 184-186.
16. Blume KG, Forman SJ, O'Donnell MR et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015-1020.
17. Zander AR, Culbert S, Jagannath S et al. High dose cyclophosphamide, BCNU and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 1987; 59: 1083-1086.
18. Giralt SA, LeMaistre CF, Vriesendrop HM et al. Etoposide, cyclophosphamide, total body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994; 12: 1923-1930.
19. Rudnick SA, Cadman EC, Capizzi RI et al. High dose cytosine arabinoside for refactory leukemia. Cancer 1979; 44: 1189-1193.
20. Herzig RH, Herzig GP, Lazarus HM et al. High dose cytosine arabinoside for refactory leukemia. Blood 1983; 62: 361-369.
21. Hines JD, Oken MM, Mazza JJ et al. High-dose cytarabine and m-AMSA is effective therapy in relapsed acute nonlymphoblastic leukemia. J Clin Oncol 1984; 2: 545-549.
22. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843.
23. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndromes after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
24. Bearman SI, Applebaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
25. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
26. Nevill TJ, Barnett MJ, Klingemann HG et al. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
27. Bandini G, Belardinelli A, Rosti G et al. Toxicity of high-dose busulfan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with hematological malignancies. Bone Marrow Transplant 1994; 13: 577-581.
28. Andersson BS, Luna MA, Yee C et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer 1990; 65: 1079-1084.
29. Riddell S, Appelbaum FR, Buckner CD et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol 1988; 6: 576-582.
30. Messner HA, Curtis JE, Minden MM. The combined use of cytosine arabinoside, cyclophosphamide, and total body irradiation as preparative regimen for bone marrow transplantation in patients with AML and CML. Semin Oncol 1985; 2: 187-189.